(SANA) – Sana Biotechnology Inks Two Licensing Pacts For Targets Against Hematological Malignancies

Sana Biotechnology Inc (NASDAQ: SANA) has obtained non-exclusive commercial rights to a clinically validated fully-human BCMA CAR construct from IASO Biotherapeutics and Innovent Biologics.

  • The constructs can be used in certain in vivo gene therapy and ex vivo hypoimmune cell therapy applications. 
  • IASO Bio and Innovent will receive an upfront payment and are entitled to receive up to approximately $204 million in potential development and regulatory milestone payments across up to six products, as well as royalties.
  • Related: Sana Obtains License To Beam Therapeutics’ CRISPR Cas12b Gene Editing Technology.
  • B cell maturation antigen (BCMA) has been validated as a target for autologous CAR T therapy in relapsed and/or refractory multiple myeloma.
  • Separately, Sana Biotechnology has entered into an agreement with the National Cancer Institution (NCI) for worldwide exclusive commercial rights to the NIH’s CD22 chimeric antigen receptor (CAR) with a fully-human binder for use in certain in vivo
Read more

The Keys to Podcasting Success in 2022 – Smart Passive Income

In this post, I’ll share some of the key trends in podcasting right now, and highlight some ideas for growing your podcast in 2022 and beyond. And join us live on YouTube tomorrow, Tuesday January 11 for OPEN Podcast #1, to learn the strategies for creating powerful podcast content!

Table of Contents

[Note: This post contains affiliate links. Read our full affiliate disclosure here.]

Podcasting Industry Growth Means Opportunity

According to data from Buzzsprout, the podcast industry has grown significantly—from roughly 60,000 shows in 2014 to more than two million today.

But this massive growth doesn’t mean prospective podcasters have missed the boat. Far from it. The podcast industry is still growing.

Plus, a lot of the people who started podcasts in early COVID have dropped off. That means a lot of listeners are out there right now, looking for their next show.

Which means an opportunity for you,

Read more